Comparative proteomic analysis to discover potential therapeutic targets in human multiple myeloma

Proteomics - Clinical Applications

Volumn 3, Issue 11, 2009, Pages 1348-1360

  Xiao, Chuan Le ^a   Zhang, Zhi Ping ^b   Xiong, Sheng ^a   Lu, Chun Hua ^a   Wei, Hong Ping ^b   Zeng, Hui Lan ^a   Liu, Zhi ^c   Zhang, Xian En ^b   Ge, Feng ^a  

^a JINAN UNIVERSITY   (China)

^b WUHAN INSTITUTE OF VIROLOGY   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Annexin A1; Multiple myeloma; Plasma cell

Indexed keywords

CELL PROTEIN; DEXAMETHASONE; LIPOCORTIN 1; PROTEOME; SYNDECAN 1;

ACCESS TO INFORMATION; ANTIGEN PURIFICATION; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOGENESIS; CLINICAL ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG RESEARCH; DRUG TARGETING; HUMAN; HUMAN CELL; IMMUNOMAGNETIC SEPARATION; INTERNET; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; TWO DIMENSIONAL ELECTROPHORESIS; WESTERN BLOTTING;

EID: 77951053453     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.200900068     Document Type: Article

References (47)

1. Mitsiades, C. S., Mitsiades, N. S., Munshi, N. C., Anderson, K. C., Focus on multiple myeloma. Cancer Cell 2004, 6, 439-444.
2. Jemal, A., Siegel, R., Ward, E., Hao, Y. et al., Cancer statistics. CA Cancer J. Clin. 2008, 58, 71-96.
3. Yang, L., Parkin, D. M., Ferlay, J., Li, L., Chen, Y., Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol. Biomarkers Prev. 2005, 14, 243-250.
4. Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G., Anderson, K. C., Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat. Rev. Cancer 2007, 7, 585-598.
5. Tassone, P., Tagliaferri, P., Rossi, M., Gaspari, M. et al., Genetics and molecular profiling of multiple myeloma, novel tools for clinical management? Eur. J. Cancer 2006, 42, 1530-1538.
6. Zhan, F., Tian, E., Bumm, K., Smith, R. et al., Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. Blood 2003, 101, 1128-1140.
7. Shi, T., Dong, F., Liou, L. S., Duan, Z. H. et al., Differential protein profiling in renal-cell carcinoma. Mol. Carcinog. 2004, 40, 47-61.
8. Mitsiades, C. S., Mitsiades, N., Treon, S. P., Anderson, K. C., Proteomic analyses in Waldenstrom's macroglobulinemia and other plasma cell dyscrasias. Semin. Oncol. 2003, 30, 156-160.
9. Ge, F., Lu, X. P., Zeng, H. L., He, Q. Y. et al., Proteomic and functional analyses reveal a dual molecular mechanism underlying arsenic-induced apoptosis in human multiple myeloma cells. J. Proteome Res. 2009, 8, 3006-3019.
10. Rees-Unwin, K. S., Craven, R. A., Davenport, E., Hanrahan, S. et al., Proteomic evaluation of pathways associated with dexamethasone-mediated apoptosis and resistance in multiple myeloma. Br. J. Haematol. 2007, 139, 559-567.
11. Jennings, C. D., Foon, K. A., Recent advances in flow cytometry, application to the diagnosis of hematologic malignancy. Blood 1997, 90, 2863-2892.
12. Mi, H., Guo, N., Kejariwal, A., Thomas, P. D., PANTHER version 6, Protein sequence and function evolution data with expanded representation of biological pathways. Nucleic Acids Res. 2007, 35, D247-D252.
13. Nikitin, A., Egorov, S., Daraselia, N., Mazo, I., Pathway studiothe analysis and navigation of molecular networks. Bioinformatics 2003, 19, 2155-2157.
14. Brito, J. L., Davies, F. E., Gonzalez, D., Morgan, G. J., Streptolysin-O reversible permeabilisation is an effective method to transfect siRNAs into myeloma cells. J. Immunol. Methods 2008, 333, 147-155.
15. Zhan, F., Hardin, J., Kordsmeier, B., Bumm, K. et al., Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002, 99, 1745-1757.
16. Ditzel, H. J., Strik, M. C., Larsen, M. K., Willis, A. C. et al., Cancer-associated cleavage of cytokeratin 8/18 heterotypic complexes exposes a neoepitope in human adenocarcinomas. J. Biol. Chem. 2002, 277, 21712-21722.
17. Janke, J., Schluter, K., Jandrig, B., Theile, M. et al., Suppression of tumorigeniciy in breast cancer cells by the microfilament protein profilin 1. J. Exp. Med. 2000, 191, 1675-1685.
18. Gronborg, M., Kristiansen, T. Z., Iwahori, A., Chang, R. et al., Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol. Cell. Proteomics 2006, 5, 157-171.
19. Wu, N., Zhang, W., Yang, Y., Liang, Y. L. et al., Profilin 1 obtained by proteomic analysis in all-trans retinoic acid-treated hepatocarcinoma cell lines is involved in inhibition of cell proliferation and migration. Proteomics 2006, 6, 6095-6106.
20. Wittenmayer, N., Jandrig, B., Rothkegel, M., Schlüter, K. et al., Tumor suppressor activity of profilin requires a functional actin binding site. Mol. Biol. Cell 2004, 15, 1600-1608.
21. Witke, W., The role of profilin complexes in cell motility and other cellular processes. Trends Cell Biol. 2004, 14, 461-469.
22. Grenklo, S., Geese, M., Lindberg, U., Wehland, J. et al., A crucial role for profilin-actin in the intracellular motility of listeria monocytogenes. EMBO Rep. 2003, 4, 523-529.
23. Schwartz, A. L., The ubiquitin-proteasome pathway and pathogenesis of human disease. Annu. Rev. Med. 1999, 50, 57-74.
24. Hernandez, F., Diaz-Hernandez, M., Avila, J., Lucas, J. J., Testing the ubiquitin-proteasome hypothesis of neurodegeneration in vivo. Trends Neurosci. 2004, 27, 66-69.
25. Kumatori, A., Tanaka, K., Inamura, N., Sone, S. et al., Abnormally high expression of proteasomes in human leukemic cells. Proc. Natl. Acad. Sci. USA 1990, 87, 7071-7075.
26. Kanayama, H., Tanaka, K., Aki,M., Kagawa, S. et al., Changes in expressions of proteasome and ubiquitin genes in human renal cancer cells. Cancer Res. 1991, 51, 6677-6685.
27. Choi, Y. H., Proteasome-mediated degradation of BRCA1 protein in MCF-7 human breast cancer cells. Int. J. Oncol. 2001, 19, 687-693.
28. Bogner, C., Schneller, F., Hipp, S., Ringshausen, I. et al., Cycling B-CLL cells are highly susceptible to inhibition of the proteasome, involvement of p27, early D-type cyclins, Bax, and caspase-dependent and -independent pathways. Exp. Hematol. 2003, 31, 218-225.
29. Schenkein, D., Proteasome inhibitors in the treatment of B-cell malignancies. Clin. Lymphoma 2002, 3, 49-55.
30. Nishinaka, Y., Nakamura, H., Masutani, H., Yodoi, J., Archiv. Immunol. Ther. Exper. 2001, 49, 285-292.
31. Crack, P. J., Taylor, J. M., Flentjar, N. J., de Haan, J. et al. Increased infarct size and exacerbated apoptosis in the glutathione peroxidase-1 (GPx-1) knockout mouse brain in response to ischemia/reperfusion injury. J. Neurochem. 2001, 78, 1389-1399.
32. Hussain, S. P., Amstad, P., He, P., Robles, A. et al., p53-induced upregulation of MnSOD and GPx but not catalase increases oxidative stress and apoptosis. Cancer Res. 2004, 64, 2350-2356.
33. Zima, T., Spicka, S., Crkovska, J., Platenik, J. et al., Antioxidant enzymes and lipid peroxidation in patients with multiple myeloma. Neoplasma 1996, 43, 69-73.
34. Kuku, I., Aydogdu, I., Bayraktar, N., Kaya, E. et al., Oxidant/ antioxidant parameters and their relationship with medical treatment in multiple myeloma. Cell Biochem. Funct. 2005, 23, 47-50.
35. Gerke, V., Moss, S. E., Annexins, from structure to function. Physiol. Rev. 2002, 82, 331-371.
36. Rescher, U., Gerke, V., Annexins-unique membrane binding proteins with diverse functions. J. Cell Sci. 2004, 117, 2631-2639.
37. Alldridge, L. C., Harris, H. J., Plevin, R., Hannon, R., Bryant, C. E., The annexin protein lipocortin 1 regulates the MAPKERK pathway. J. Biol. Chem. 1999, 274, 37620-37628.
38. Solito, E., Kamal, A., Russo-Marie, F., Buckingham, J. C. et al., A novel calcium-dependent proapoptotic effect of annexin 1 on human neutrophils. FASEB J. 2003, 17, 1544-1546.
39. Rodrigues-Lisoni, F. C., Mehet, D. K., Peitl, P., John, C. D. et al., In vitro and in vivo studies on CCR10 regulation by Annexin A1. FEBS Lett. 2006, 580, 1431-1438.
40. Gerke, V., Moss, S. E., Annexins, from structure to function. Physiol. Rev. 2002, 82, 331-371.
41. Bai, X. F., Ni, X. G., Zhao, P., Liu, S.M. et al., Overexpression of annexin 1 in pancreatic cancer and its clinical significance. World J. Gastroenterol. 2004, 10, 1466-1470.
42. Falini, B., Tiacci, E., Liso, A., Basso, K. et al., Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). Lancet 2004, 363, 1869-1870.
43. Hummerich, L., Muller, R., Hess, J., Kokocinski, F. et al., Identification of novel tumour-associated genes differentially expressed in the process of squamous cell cancer development. Oncogene 2006, 25, 111-121.
44. Croxtall, J. D., Flower, R. J., Lipocortin-1 mediates dexamethasone-induced growth arrest of the A549 lung adenocarcinoma cell line. Proc. Natl. Acad. Sci. USA 1992, 89, 3571-3575.
45. Wu, Y. L., Jiang, X. R., Lillington, D. M., Newland, A. C., Kelsey, S. M., Upregulation of lipocortin 1 inhibits tumour necrosis factor-induced apoptosis in human leukaemic cells, a possible mechanism of resistance to immune surveillance. Br. J. Haematol. 2000, 111, 807-816.
46. Kornblau, S. M., Tibes, R., Qiu, Y. H., Chen, W. et al., Functional proteomic profiling of AML predicts response and survival. Blood 2009, 113, 154-164.
47. Fontana, S., Alessandro, R., Barranca, M., Giordano, M. et al., Comparative proteome profiling and functional analysis of chronic myelogenous leukemia cell lines. J. Proteome Res. 2007, 6, 4330-4342.